DREAM organization
See the following -
Research Symbiosis Makes Mathematical Crystal Ball to Gaze into Future of Prostate Cancer Treatment
Press Release |
University of Colorado Cancer Center |
August 4, 2017
The chemotherapy docetaxel is widely accepted as a standard therapy for metastatic castration-resistant prostate cancer. But 10-20 percent of patients will have adverse side effects that force discontinuation of treatment. These patients may have been better off with another treatment in the first place, but who’s to know before trying the drug which patients will go on to experience debilitating side effects? A crowdsourced competition asked this as an open question. Today in the Journal of Clinical Oncology Clinical Cancer Informatics, competition organizers and participating teams report their findings...
- Login to post comments